PROTAC technology for sensitizing melanoma to immune checkpoint therapy

Journal of Experimental & Clinical Cancer Research · Published 2026-08-03 · DOI 10.1186/s13046-026-03799-z

Free full text

Authors (6)

Qiujun Zhou, Xiaowei Zhang, Chenlu Zhao, Difei Chen, Chen Chu, Xiaoliang Jin

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhou, Q., Zhang, X., Zhao, C., et al. (2026). PROTAC technology for sensitizing melanoma to immune checkpoint therapy. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03799-z

Related articles

• Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Targeting the lipid desaturation network in cancer: from metabolic plasticity to precision therapeutics · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Inhibition of 5’-tiRNAGly restores anti-PD-1 immunotherapy efficacy via DLST-mediated OGDHL succinylation in gastric cancer · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Beyond conventional immune checkpoints: the LILRB axis as a dual regulator of tumor and immune cell states · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Soulangianolide A targets FAM120A to disrupt SREBP1-driven lipid metabolic reprogramming and suppress clear cell renal cell carcinoma · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Extracellular vesicle–mediated GALNT1/RPRD1A glycosylation axis drives immune escape and peritoneal metastasis in gastric cancer · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Targeting immunoglobulin superfamily member 9 (IGSF9) to overcome acute myeloid leukemia resistance to CAR-T therapy · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• ASCL2-mediated macrophage-myofibroblast transition generates immunosuppressive CAF_7 in NSCLC bone metastases · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal
• Cancer therapy resistance converges on immune evasion: a unified framework from immunotherapy to targeted, endocrine, and DNA repair pathways · Journal of Experimental & Clinical Cancer Research · 2026 · Same journal